Explore a research direction

Pharmacology and drug discovery
research labs.

Explore labs that list pharmacology and drug discovery among their research interests, including work on how drugs act and how new therapies are found. Each profile links to its official sources so you can check what a group actually studies before you decide whom to contact.

What to compare

When comparing groups in pharmacology and drug discovery, look at screening, chemistry and computational approaches, and the stage of work from target to preclinical testing. Ask how a new researcher would be involved and what preparation is expected.

Profiles appear here because their listed research keywords match this topic. Inclusion does not establish an open position. Check the official sources and any published application instructions before reaching out.

Prepare a research introduction ↗

14 research-led lab profiles

Browse labs by their listed college affiliation
BSIndependently curated · Unclaimed
↗

Brent Stockwell Research Group

Columbia University

Brent Stockwell · Professor of Chemistry

How can small molecules reveal the biochemical mechanisms governing cell death? The research group of Brent Stockwell works at the interface of chemistry and biology, using small organic molecules to perturb cellular processes. His research involves small molecules used to understand and treat cancer and neurodegeneration. The approach is interdisciplinary, combining chemical design and synthesis with genomics, computational chemistry, biochemistry and cell biology. The laboratory is particularly interested in cell death mechanisms in mammalian systems and how they intersect with disease mechanisms in cancer and neurodegeneration.

ferroptosiscell deathchemical biology
CNIndependently curated · Unclaimed
Microbiology & Immunology↗

Carl Nathan Research Group

Cornell University

Carl Nathan · Professor

How do macrophages and Mycobacterium tuberculosis interact during infection? Carl Nathan is listed as Professor and Chair of Microbiology & Immunology at Weill Cornell Medical in New York City. The lab studies host pathways controlling susceptibility and resistance to Mtb. The lab also studies the biology of Mtb in non-replicating states. The lab is developing new kinds of antimicrobial molecules to overcome the phenotypic resistance of non-replicating Mtb to most antibiotics.

host-pathogen interactionsmacrophagesMycobacterium tuberculosis
JSIndependently curated · Unclaimed
↗

Jimeng Sun Research Group

University of Illinois at Urbana-Champaign

Jimeng Sun · Professor

How can artificial intelligence be used to improve healthcare, from drug discovery and clinical trials to health monitoring and treatment recommendation? Jimeng Sun's research includes deep learning for drug discovery, clinical trial optimization, and computational phenotyping. It also covers clinical predictive modeling, treatment recommendation, and health monitoring. He teaches courses on deep learning for healthcare and AI in medicine. His research interests include data and information systems, bioinformatics and computational biology, and artificial intelligence.

AI for healthcaredeep learningdrug discovery
KLIndependently curated · Unclaimed
↗

Le Roch Lab

University of California, Riverside

Karine Le Roch · Professor of Molecular, Cell and Systems Biology

Malaria parasites depend on carefully regulated gene activity to develop and survive. Le Roch’s laboratory investigates the molecular pathways underlying that biology using functional genomics and drug discovery approaches. Research includes chromatin structure, epigenetic regulation, and long noncoding RNAs in apicomplexan parasites such as Plasmodium falciparum. High throughput methods help identify pathways involved in parasite and host cell development. The group asks how RNA and chromatin regulation work and whether understanding those mechanisms could reveal new therapeutic approaches to parasitic disease.

MalariaFunctional genomicsEpigenetics
MSIndependently curated · Unclaimed
Internal Medicine↗

Michael Sanguinetti Research Group

University of Utah

Michael Sanguinetti · Professor in the Division of Cardiology

What are the properties of cardiac ion channels, and what is the molecular basis of inherited arrhythmia? Michael Sanguinetti is a Professor in the Division of Cardiology at the University of Utah. His research laboratory is located at the Nora Eccles Harrison Cardiovascular Research and Training Institute. His research interests include cellular cardiac electrophysiology, ion channel biophysics and pharmacology, and the molecular basis of inherited arrhythmia. He uses biophysical and molecular biological techniques to study the properties of cardiac ion channels.

cardiac electrophysiologyion channel biophysicsinherited arrhythmia
PJIndependently curated · Unclaimed
Professor of Chemistry↗

Paul J. Hergenrother Research Group

University of Illinois at Urbana-Champaign

Paul J. Hergenrother · Professor of Chemistry

Which small organic compounds selectively kill cancer cells or drug-resistant bacteria and by what mechanisms? Hergenrother's group designs, synthesizes, and evaluates organic molecules with novel biological properties, including enzyme modulators and anticancer and antibacterial compounds. Projects include Complexity-to-Diversity (CtD) synthesis of diverse compounds from natural products and high-throughput screening to identify biologically active molecules. Researchers apply structure-based design, medicinal chemistry, and biological assays, including tests on patient samples, to identify personalized anticancer targets such as procaspase-3 activation and NQO1-selective agents. The group develops predictive rules and synthesis strategies to produce compounds active against Gram-negative pathogens.

organic chemistrynatural productschemical biology
PWIndependently curated · Unclaimed
Chemistry↗

Peter Wipf Research Group

University of Pittsburgh-Pittsburgh campus

Peter Wipf · Distinguished University Professor of Chemistry

Can novel synthetic and medicinal-chemistry methods yield small molecules that modulate challenging biological targets? The Wipf Group pursues total synthesis, strain-release and heterocyclic chemistry to access diverse scaffolds for biological testing. Medicinal-chemistry and structure–activity studies optimize small molecules as inhibitors or modulators of protein targets, including p97/VCP and PTP4A3, with the goal of generating probes and therapeutic leads. Collaborative translational projects apply these compounds in cancer, neurodegeneration, and radiation-mitigation studies.

organic chemistrymedicinal chemistrytotal synthesis
RBIndependently curated · Unclaimed
Department of Computer Science↗

Regina Barzilay Research Group

Massachusetts Institute of Technology

Regina Barzilay · School of Engineering Distinguished Professor for AI and Health

Can machine learning detect cancer risk from routine clinical imaging before symptoms appear to enable earlier intervention? The group develops deep-learning models for personalized mammography-based risk prediction and early cancer detection. Researchers build ML methods for de-novo molecular design and retrosynthesis to change traditional drug-discovery pipelines toward data-driven generation. The team develops generative models such as BoltzGen to create protein binders for biological targets and tools like VaxSeer to predict virus evolution for vaccine strain selection. They also focus on interpretability and robustness for clinical AI to support safer, fairer deployment in healthcare settings.

machine learninghealthcaremedical imaging
SGIndependently curated · Unclaimed
Institute for Tuberculosis Research↗

Scott Gary Franzblau Research Group

University of Illinois Chicago

Scott Gary Franzblau · Albert Schatz Professor of Medicinal Chemistry and Pharmacognosy

How can new drugs for tuberculosis be found by the Institute for Tuberculosis Research led by Scott Gary Franzblau? Scott Gary Franzblau is the Director of the Institute for Tuberculosis Research and the Albert Schatz Professor of Medicinal Chemistry and Pharmacognosy. The institute pursues large scale screening of both natural and synthetic compounds for those that demonstrate specificity of activity. Lead compounds are then optimized by semi-synthesis. Activity of all lead compounds is assessed in macrophage and mouse models of TB.

tuberculosisdrug discoveryanti-TB agents
SLIndependently curated · Unclaimed
Chemistry↗

Shih‐Yuan Liu Research Group

Boston College

Shih‐Yuan Liu · Professor of Chemistry

How can boron-nitrogen-containing heterocycles, specifically azaborines, be developed? Shih-Yuan Liu is engaged in synthetic chemistry with emphasis on developing molecules of importance in biomedical research and materials science. Azaborines are structures resulting from the replacement of two carbon atoms in benzene with a boron and a nitrogen atom. Azaborines are isosteres of the important family of benzenoid compounds, or arenes. Areas of exploration include organic synthesis, catalysis, hydrogen storage, optoelectronic materials, and drug discovery.

azaborinesboron-nitrogen heterocyclessynthetic chemistry
SWIndependently curated · Unclaimed
Biochemistry↗

Stephen W. Fesik Research Group

Vanderbilt University

Stephen W. Fesik · Professor of Biochemistry, Pharmacology, and Chemistry

Can fragment-based methods and structure-based design be used to find drugs for hard-to-drug cancer targets? Stephen Fesik is a Professor of Biochemistry, Pharmacology and Chemistry who holds the Orrin H. Ingram II Chair in Cancer Research. The Fesik lab uses fragment-based methods to identify small molecules, called fragments, that bind to difficult targets and structure-based design to optimize them for binding to the target protein. Current projects include discovery of KRAS inhibitors, WDR5 inhibitors and MYC/MAX inhibitors. The lab also works on the development of new NMR methods for fragment screening.

drug discoverycancerNMR
UBIndependently curated · Unclaimed
↗

Ulrich Bierbach Research Group

Wake Forest University

Ulrich Bierbach · Professor

Bierbach designs drug candidates that combine organic molecules with metal-based chemistry. His laboratory investigates platinum-acridine hybrid anticancer agents, linking chemical structure with biological activity and mechanisms of action. Research listed by Wake Forest includes identifying DNA targets, examining how membrane transport influences activity, and studying relationships between gene expression and drug sensitivity. The group also explores delivery formulations, including liposomal approaches. This is a preclinical research setting for people interested in medicinal and inorganic chemistry, where synthesizing a compound is paired with investigating how it reaches and affects cancer cells.

Medicinal chemistryPlatinum-acridineCancer therapeutics
YWIndependently curated · Unclaimed
Health Outcomes & Biomedical Informatics↗

Yonghui Wu Research Group

University of Florida

Yonghui Wu · Professor & Chief Data Scientist

How can natural language processing and large language models improve medical discovery and healthcare? Yonghui Wu is a Professor with Tenure in the Department of Health Outcomes & Biomedical Informatics, College of Medicine at the University of Florida. He is also the Chief Data Scientist & Director of Natural Language Processing (NLP) at the UF Clinical and Translational Science Institute (CTSI). His research interests include NLP, large language models (LLMs), Agentic Artificial Intelligence (AI), machine learning, and computational drug discovery using electronic health records (EHRs). He has a strong track record of building AI models and informatics tools to advance medical discovery and healthcare.

natural language processinglarge language modelsmachine learning
ZZIndependently curated · Unclaimed
Medicinal Chemistry and Molecular Pharmacology↗

Zhong-Yin Zhang Research Group

Purdue University West Lafayette

Zhong-Yin Zhang · Distinguished Professor of Medicinal Chemistry

How can protein tyrosine phosphatases be targeted to control disease progression? The research spans chemistry and biology with an emphasis on protein tyrosine phosphatases (PTPs), enzymes that regulate cellular processes. These enzymes remove phosphoryl groups from tyrosine phosphorylated proteins. Abnormal PTP activity leads to aberrant cellular signaling linked to the development of cancer, diabetes and obesity, neurodegenerative and autoimmune disorders, and infectious diseases. Zhong-Yin Zhang is also Director of the Purdue Institute for Drug Discovery.

protein tyrosine phosphataseschemical biologydrug discovery

Showing 1–14 of 14 labs

Explore the listed universities